ViroPharma Stock Rating Reaffirmed by Zacks (VPHM)
ViroPharma (NASDAQ:VPHM)‘s stock had its “neutral” rating reiterated by Zacks in a report released on Tuesday, American Banking & Market News reports. They currently have a $42.00 target price on the stock. Zacks‘ target price would suggest a potential upside of 5.77% from the stock’s previous close.
Zacks‘ analyst wrote, “ViroPharma reported earnings of a penny per share in the second quarter of 2013 compared to a loss of $0.06 per share in the year-ago quarter. The Zacks Consensus Estimate was $0.02 per share. Quarterly revenues, which increased 9.5% year over year to $103.7 million, were marginally short of the Zacks Consensus Estimate of $105 million. The year-over-year growth in revenues was fuelled by Cinryze sales in the U.S. and higher product sales in Europe. The growth story for ViroPharma revolves around Cinryze which accounted for more than 75% of total revenues in 2012. However, the discontinuation of a phase II study on the label expansion of its key drug is a setback for the company. Although positive on the growth prospects of Cinryze, we are concerned about the company’s increasing dependence on the same going forward. We initiate our coverage on ViroPharma with a Neutral recommendation.”
Shares of ViroPharma (NASDAQ:VPHM) traded down 1.24% during mid-day trading on Tuesday, hitting $39.71. 931,785 shares of the company’s stock traded hands. ViroPharma has a one year low of $22.12 and a one year high of $41.14. The stock’s 50-day moving average is $34.92 and its 200-day moving average is $29.72. The company’s market cap is $2.602 billion.
ViroPharma (NASDAQ:VPHM) last issued its quarterly earnings data on Thursday, August 1st. The company reported $0.15 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.01 by $0.14. The company had revenue of $104.00 million for the quarter, compared to the consensus estimate of $105.06 million. During the same quarter in the previous year, the company posted ($0.06) earnings per share. The company’s revenue for the quarter was up 9.6% on a year-over-year basis. On average, analysts predict that ViroPharma will post $-0.78 earnings per share for the current fiscal year.
A number of other firms have also recently commented on VPHM. Analysts at Ned Davis Research downgraded shares of ViroPharma from a “neutral” rating to a “sell” rating in a research note to investors on Monday, September 30th. Separately, analysts at Deutsche Bank downgraded shares of ViroPharma from a “buy” rating to a “hold” rating in a research note to investors on Thursday, September 19th. They now have a $43.00 price target on the stock, up previously from $38.00. Finally, analysts at Merrill Lynch downgraded shares of ViroPharma from a “buy” rating to a “neutral” rating in a research note to investors on Wednesday, September 18th. Two analysts have rated the stock with a sell rating, seven have assigned a hold rating and six have given a buy rating to the company’s stock. The stock currently has a consensus rating of “Hold” and an average price target of $37.96.
ViroPharma Incorporated (NASDAQ:VPHM) is an international biotechnology company.
To view Zacks’ full report, visit www.zacks.com
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.